KYTX today
$5.03-$0.09 (-1.76%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourBearish
15 minExpanding
5 minBearish
Daily trend turns up above $6.12
Key levels
Resistance$5.61
Resistance$5.16
Support$4.50
Support$3.78
Latest news & SEC filings
EarningsKyverna Therapeutics posts Q3 2026 results and finishes Miv-cel filing
EarningsKyverna Therapeutics posts smaller quarterly loss than expected
ProductKyverna Therapeutics seeks priority review for miv-cel in SPS after filing
SEC FilingKyverna Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All KYTX news →About Kyverna Therapeutics
Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell-based treatments for autoimmune diseases. Its lead candidate, mivocabtagene autoleucel (miv-cel), is a patient-derived therapy that targets B cells via the CD19 marker and is under study in neurologic conditions such as stiff person syndrome and generalized myasthenia gravis, and in multiple sclerosis, rheumatoid arthritis, lupus nephritis, and systemic sclerosis. The company also pursues newer cell therapy platforms and manufacturing methods. It operates in the United States and has provided its therapy to patients in Germany.
Based on the company's 10-K filed Mar 26, 2026.
Nasdaq · Healthcare
Kyverna Therapeutics, Inc. (KYTX)
What Is the Price Target for KYTX?
SEPT Low Target
$25.00
SEPT Mid Target
$25.00
SEPT High Target
$29.00
Analyst Consensus
$25.00
Is KYTX a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for KYTX.
Start Free Trial →Is KYTX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$20.51
12
Moat Score
NONE
1/9
Piotroski Score
-0.7
Altman Z-Score
What Is Smart Money Doing with KYTX?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| CLARK IAN T | director | Buy | 5,093 | - | May 27, 2026 |
| Cohen Fred E | director | Buy | 5,093 | - | May 27, 2026 |
| SEIDENBERG BETH C | director | Buy | 5,093 | - | May 27, 2026 |
| Shaw Christi | director officer | Sale | 4,194 | $36K | May 27, 2026 |
| Aktar Mert | director | Buy | 5,093 | - | May 27, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →KYTX Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-9.31%
FCF Growth YoY
-32.0%
Revenue Trend
UNKNOWN
Dark Pool Trades for KYTX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for KYTX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 23:03:09 | $5.00 | 3,316 | $$17K | SELL |
| 21:00:10 | $5.03 | 5,139 | $$26K | SELL |
| 21:00:10 | $5.03 | 2,312 | $$12K | SELL |
| 21:00:10 | $5.03 | 2,648 | $$13K | SELL |
| 21:00:10 | $5.03 | 3,303 | $$17K | SELL |
5 dark pool trades shown · $$84K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for KYTX
PREVIEWSEPT Investing provides real-time options flow tracking for KYTX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $7.5 | Nov 20 | 8 | $$24.7K | 95 | SWEEP |
| PUT | $7.5 | Jun 17 | 217 | $$330 | 1 | SWEEP |
| PUT | $5 | Jun 17 | 217 | $$125 | 1 | SWEEP |
| PUT | $7.5 | Jun 17 | 217 | $$310 | 1 | SWEEP |
| PUT | $5 | Jun 17 | 217 | $$140 | 1 | SWEEP |
5 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Kyverna Therapeutics, Inc. (KYTX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →KYTX — frequently asked questions
What is KYTX stock price today?
Kyverna Therapeutics, Inc. (KYTX) is at $5.03, down 1.76% (-$0.09) at the Nov 12, 2026 close.
Why is KYTX stock down today?
Nov 12, 2026: Kyverna Therapeutics reported a third-quarter loss of $0.68 per share, slightly better than the $0.69 loss analysts expected, while also disclosing it has filed for priority review of miv-cel in SPS and confirmed that enrollment in the KYSA-6 Phase 3 gMG study remains on track to complete in mid-2027. Despite these bullish developments, the stock closed down 4.91% at $5.03, trading between a low of $4.76 and a high of $5.29 on volume of about 1.07 million shares.
What is the KYTX price target?
The average analyst price target for KYTX is $25.00, ranging from $25 to $29, based on 3 analysts.
What do analysts rate KYTX?
Analyst ratings for KYTX: 0 Buy, 4 Hold, 0 Sell — consensus Hold.
Did KYTX beat earnings?
KYTX last reported on Aug 11, 2026: EPS -$0.63 vs -$0.68 expected — a beat of 7.1%.
Does KYTX pay a dividend?
KYTX does not currently pay a dividend.
What are KYTX support and resistance levels?
Support: $4.50, $3.78, $3.37. Resistance: $5.16, $5.61, $6.12.
What are insiders doing with KYTX?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on KYTX?
Nov 12, 2026: Kyverna Therapeutics posts Q3 2026 results and finishes Miv-cel filing · Nov 12, 2026: Kyverna Therapeutics posts smaller quarterly loss than expected · Nov 12, 2026: Kyverna Therapeutics seeks priority review for miv-cel in SPS after filing